NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that the company’s i-Lid Cleanser with Neutrox has been featured in a recently published edition of the Review of Optometry.
The Review of Optometry article describes new treatment options for blepharitis. More than 23 million Americans suffer from this condition, where bacteria grow on eyelids, causing swelling, redness, inflammation, irritation and a crusty build-up.
As the article describes, i-Lid Cleanser contains pure hypochlorous acid (HOCl). “HOCl is naturally produced by neutrophils in response to pathogenic organisms, and can kill bacteria, block bacterial-derived toxins and blunt the effects of human cell-derived pro-inflammatory mediators,” the article explains.
i-Lid Cleanser comes in a glass bottle with a pump sprayer, the article says, making it easy for patients to spray it onto a cotton ball or gauze, which they then use to wipe their eyes. The authors, Alan G. Kabat, OD, and Joseph W. Sowka, OD, report that the results have been good. “Colleagues employing the product in their blepharitis treatment regimen have noted substantial improvement in both signs and symptoms when applied BID for just 10 days,” they write.
“The Review of Optometry is a key source of clinical information for optometrists, so we are pleased that the publication has recognized the benefits of i-Lid Cleanser,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. “Once optometrists try i-Lid Cleanser and see the results, we believe they will quickly realize that it offers a key improvement in the standard of care for common conditions like blepharitis and dry eye syndrome.”
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
For investor information, please contact:
Thomas J. Paulson
Chief Financial Officer
Contact T. Paulson
This release contains forward-looking statements and opinions regarding the commercial potential of i-Lid Cleanser, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the actual effectiveness and market acceptance of NovaBay products. Other risks relating to NovaBay and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.